Evidence map›Paper›PMID 29921503›Full record

ArticleJournal of cystic fibrosis : official journal of the European Cystic Fibrosis Society2018

Characteristics and outcomes of oral antibiotic treated pulmonary exacerbations in children with cystic fibrosis.

Jordana E Hoppe, Brandie D Wagner, Frank J Accurso, Edith T Zemanick, Scott D Sagel

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Article
  3. Diagnosis and Management of Cystic Fibrosis Exacerbations.Seminars in respiratory and critical care medicine · 2023
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Jordana E HoppeDepartment of Pediatrics, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, CO, USA. Electronic address: jordana.hoppe@childrenscolorado.org.
Brandie D WagnerDepartment of Pediatrics, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, CO, USA; Department of Biostatistics and Informatics, University of Colorado School of Public Health, Aurora, CO, USA.
Frank J AccursoDepartment of Pediatrics, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, CO, USA.
Edith T ZemanickDepartment of Pediatrics, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, CO, USA.
Scott D SagelDepartment of Pediatrics, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, CO, USA.

Funding

Colorado Clinical and Translational Sciences InstituteUL1TR001082 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2013 to 2017
$48.0M
Airway Microbiome in Cystic Fibrosis Pulmonary ExacerbationsK23HL114883 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI ZEMANICK, EDITH TOWLER · 2014 to 2017
$615k
NCATS NIH HHS UL1 TR001082NHLBI NIH HHS K23 HL114883
6 · The paper itself

Abstract

backgroundPulmonary exacerbations (PEx) in children with cystic fibrosis (CF) are frequently treated in the outpatient setting with oral antibiotics. However, little is known about the characteristics of PEx managed on an outpatient basis and the effectiveness of oral antibiotic therapy. We sought to prospectively evaluate clinical and laboratory changes associated with oral antibiotic treatment for PEx.

methodsChildren with CF between 8 and 18 years of age prescribed two weeks of oral antibiotics for a PEx were eligible to enroll. The study consisted of a visit within 48 h of starting antibiotics and a second visit within one week of antibiotic completion. Twenty-eight participants were evaluated by exacerbation score, quality of life measurements, lung function, sputum microbiology and inflammation.

resultsOral antibiotic treatment was associated with a significant improvement in exacerbation score and quality of life measured by the CF Questionnaire-Revised (CFQ-R) respiratory domain. Following treatment, forced expiratory volume in 1 s (FEV

conclusionsTreatment of PEx with oral antibiotics was associated with measurable improvements in patient reported outcomes, lung function, bacterial density and sputum inflammatory markers.

Indexed as

Anti-Bacterial AgentsLung DiseasesQuality of LifeAdministration, OralAdolescentBacteriaChildCystic FibrosisFemaleHumansMaleRespiratory Function TestsTreatment OutcomeUnited StatesAnti-Bacterial AgentsCystic fibrosisInfectionInflammationLung functionPulmonary exacerbation

Identifiers

PMID29921503
PMCPMC7105204

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.